20 (AIDX) EBITDA Margin (2025 - 2026)
20 (AIDX) posted EBITDA Margin of 408.45% for Q1 2026, down 192.95% on a QoQ basis from 139.43% in Q1 2025, and down 26902.0% year-over-year from N/an in Q1 2025.
20 (AIDX) EBITDA Margin (2025 - 2026) Analysis & Trends
20's EBITDA Margin history runs 2 years deep, the most recent figure standing at 408.45% for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.52 Bn | 175.22 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 128.96 Bn | 126.09 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 107.99 Bn | 98.77 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 67.76 Bn | 66.31 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 48.09 Bn | 44.41 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 28.30 Bn | 27.18 Bn | 750.30 Mn | 21.42% |
| 7 | GE HealthCare Technologies | 27.89 Bn | 25.61 Bn | 1.98 Bn | 10.04% |
| 8 | Smith & Nephew | 27.02 Bn | 26.45 Bn | - | - |
| 9 | Koninklijke Philips | 23.98 Bn | 20.86 Bn | 2.07 Bn | 6.17% |
| 10 | 20 | 3.47 Mn | -747,311.48 | 62,884.00 | -408.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -408.45% |
| Mar 31, 2025 | -139.43% |